Category Archives: Events

Latest From Events

Stretching Your Dollar: Methods and Tools for Increasing the Productivity of Clinical Trials

admin-ajax.php

Recent Tufts data show clinical trials typically take nearly twice as long to complete enrollment as predicted at launch and 48% of trial sites miss enrollment targets.  Delays in trials shrink the returns from patent exclusivity and increase R&D costs.  New methods such as adaptive and batch trial designs, as well as explosive growth in digital tools, such as Apple’s ResearchKit, have transformed the trial design choices available.  These innovations, and others, provide new levers Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Fireside Chat: James Noble Says Go for IPO

james-noble1

“Go for it,” was the parting advice James Noble, CEO and co-founder of Adaptimmune, had for pre-IPO biotech companies attending today’s BIO Investor Forum fireside chat. But, he said, be prepared for scrutiny from all sides… and mountains of paperwork. James co-founded Adaptimmune, a clinical-stage immunotherapy biopharmaceutical company, in July of 2008. At that time he was also part-time CEO of Immunocore, also a clinical-stage company engaged in T-cell receptor researches and develop. From this Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

To even the most casual observer, 2015 has been a big year in the biotech industry, particularly in Congress and in other venues wherein public policies that affect the sector take shape. Given the importance of the policy environment in determining how successful companies in our industry can be at delivering new cures and treatments to patients – and a return to the investors who finance their activities – we decided that a close look Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Investor Forum Session Recap: Precision Medicine: Leveraging National Genomic Databases for Therapy Development (U.S., UK, Iceland)

BIF-1

As the price point for full genome analysis falls through the $1,000 per person milestone, national efforts are ramping up for large studies that should enable much more personalized therapies.  This data should accelerate drug development by clarifying genetic targets and the most appropriate patient sub-groups for clinical trials. At the 14th Annual  BIO Investors Forum in San Francisco, a panel of precision medicine experts came together to share their perspectives on the current state Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Investor Forum Newly Added Sessions – Digital Health Spotlights

hyde pier

We are pleased to announce that two “digital health spotlight” sessions have been added to next week’s BIO Investor Forum program! If you haven’t yet registered, we encourage you to do so by clicking here an to check out the full program. Digital Health Spotlight #1—Investment Landscape and CEO Interview (Tuesday, October 20, 8:00-8:55am) Recent advances in mobile applications, miniaturization, and standards interoperability, plus the rising acceptance of patients willing to share healthcare interactions through digital channels, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,